+2,568.1%
ELV vs GSK
+202.3%
+2,365.8%
-67.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.5% | -0.6% | -0.3% |
| 7D | +1.0% | +1.1% | -0.2% | +0.4% |
| 30D | +0.4% | +6.3% | -6.0% | -2.5% |
| 3M | +8.4% | +1.8% | +6.6% | +7.1% |
| 6M | +8.4% | +1.7% | +6.8% | +6.6% |
| YTD | +24.4% | +6.5% | +17.8% | +18.4% |
| 1Y | +33.5% | +9.5% | +24.0% | +25.5% |
| 3Y | -2.1% | +65.3% | -67.4% | -26.5% |
| 5Y | +5.8% | +43.7% | -37.9% | -16.2% |
| 10Y | +268.9% | +104.1% | +164.8% | +145.5% |
| All | +2,568.1% | +202.3% | +2,365.8% | +1,148.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling